Abbott Laboratories indicated as Neutral By Goldman Sachs
- Author: Zachary Reyes May 19, 2017,
May 19, 2017, 0:40
The company's stock had a trading volume of 929,541 shares. MA now owns 51,895,715 shares of the healthcare product maker's stock valued at $2,304,690,000 after buying an additional 17,633,631 shares in the last quarter. The short interest to Abbott Labs's float is 0.79%. Its up 2.49% from 13.26M shares previously.
Earnings per share (EPS) breaks down the profitability of the company on a single share basis, and for Abbott Laboratories the EPS stands at 0.48 for the previous quarter, while the analysts predicted the EPS of the stock to be 0.43, suggesting the stock exceeded the analysts' expectations. It has by 0.00% the S&P500. "Outperform View" rating was revealed by 4 and "Underperform Signal" rating was issued by 2. On Thursday, August 18 the stock rating was maintained by Needham with "Buy". The company was maintained on Wednesday, April 19 by Stifel Nicolaus. Jefferies has "Buy" rating and $48 target. The rating was maintained by RBC Capital Markets with "Outperform" on Thursday, January 26. The firm has "Buy" rating by Needham given on Thursday, December 1. The rating was initiated by UBS with "Neutral" on Tuesday, September 22. Its up 0.05, from 0.96 in 2016Q3. Shelter Insur Retirement Plan accumulated 79,700 shares. Usca Ria Lc owns 36,575 shares or 0.22% of their United States portfolio. Carderock Cap Mgmt holds 0.23% or 11,790 shares. (NASDAQ:SNPS) for 2.10 million shares. Boston & reported 56,672 shares. State Of New Jersey Common Pension Fund D reported 0.05% in Synopsys, Inc. Apple Inc (NASDAQ:AAPL) was raised too. Davidson reported 10,442 shares. Investors of record on Friday, April 14th were given a $0.265 dividend. The Delaware-based Brandywine Trust Co has invested 5.88% in the stock.
On 1/31/2017 Heather L Mason, Insider, sold 35,700 with an average share price of $40.77 per share and the total transaction amounting to $1,455,489.00. Regions Finance has invested 0.01% in Synopsys, Inc. 970 shares were sold by Watkin Jared, worth $44,028 on Tuesday, February 28. $2.84M worth of Synopsys, Inc. Shares for $34,240 were sold by Contreras Jaime. Koshinski Asset Mngmt owns 5,706 shares. The shares were sold at an average price of $43.95, for a total value of $184,590.00. Over the last 90 days, insiders sold 52,692 shares of company stock valued at $2,374,632.
Veriteq Corporation is a medical technology holding firm that operates as an online retailer of orthopedic braces and physical therapy and rehabilitation equipment through its subsidiary, Brace Shop, LLC. It has a 0.01 P/E ratio. It also offers IP products, which are pre-designed circuits that engineers use as components of larger chip creates rather than designing those circuits themselves.
Earnings per share (EPS) is the portion of a company's profit allocated to each outstanding share of common stock.
Since December 14, 2016, it had 3 insider buys, and 19 insider sales for $7.33 million activity. Indiana-based 1St Source Comml Bank has invested 0.18% in Abbott Laboratories (NYSE:ABT). This Beta value of Abbott Laboratories (ABT) shows that it has historically moved 157% for every 100% move in the benchmark. The insider Ford Robert B bought $499,345. Shares for $93,776 were sold by Salvadori Daniel Gesua Sive. The 52 week high Abbott Laboratories's shares have reached is 45.84 whilst the 52 week low for the company's shares is 36.76. Therefore 53% are positive. Abbott Laboratories had 49 analyst reports since July 24, 2015 according to SRatingsIntel. Finally, Zacks Investment Research downgraded shares of Abbott Laboratories from a "hold" rating to a "sell" rating in a report on Monday, April 10th.
Analysts on average have given a price target of $48.27 to Abbott Laboratories (ABT) stock. William Blair downgraded Abbott Laboratories (NYSE:ABT) on Friday, January 29 to "Market Perform" rating. Edward Jones upgraded the stock to "Buy" rating in Tuesday, June 21 report. The stock of Abbott Laboratories (NYSE:ABT) earned "Overweight" rating by Barclays Capital on Wednesday, October 7.
4/19/2017-Morgan Stanley Reiterated Rating of Equal Weight. RBC Capital Markets maintained it with "Outperform" rating and $55 target in Thursday, July 23 report. "Ultimately, through all this investigation into the company's performance the analyst decides whether their stock is a "buy", sell" or hold".
Investors sentiment increased to 1.01 in Q4 2016.
Several hedge funds and other institutional investors have recently modified their holdings of ABT. Nippon Life Ins Company holds 315,005 shares or 0.24% of its portfolio. Brown Advisory Incorporated holds 619,613 shares or 0.08% of its portfolio. Df Dent & has invested 0.01% in Abbott Laboratories (NYSE:ABT).
Shares of Abbott Laboratories closed the previous trading session at 43.69 down -0.35 -0.79% with 7,159,346 shares trading hands. Abbott Laboratories earned a news impact score of 0.11 on Alpha One's scale. Wagner Bowman Management Corp raised its position in shares of Abbott Laboratories by 6.6% in the third quarter. Stokes & Hubbell Capital Management LLC boosted its stake in shares of Abbott Laboratories by 1.0% in the first quarter.